CU23244A1 - Formulacion vacunal potenciada por la combinacion de un adn con un antigeno - Google Patents
Formulacion vacunal potenciada por la combinacion de un adn con un antigenoInfo
- Publication number
- CU23244A1 CU23244A1 CU20010171A CU20010171A CU23244A1 CU 23244 A1 CU23244 A1 CU 23244A1 CU 20010171 A CU20010171 A CU 20010171A CU 20010171 A CU20010171 A CU 20010171A CU 23244 A1 CU23244 A1 CU 23244A1
- Authority
- CU
- Cuba
- Prior art keywords
- antigen
- components
- potentiated
- dna
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Abstract
Formulacion de antígenos vacunales, la cual contiene como componentes principales: a-) uno o varios ADN que expresan una o varias proteínas en el individuo inmunizado y b-) un antígeno viral, en proporciones adecuadas. La novedad de la invencion estA dada por el efecto potenciador que ejerce al menos uno de los componentes sobre la respuesta inmune generada contra el otro. Desarrollo de nuevas formulaciones, minimizando el nUmero de componentes que sean capaces de ampliar y potenciar el espectro de respuesta inmune contra diferentes entidades patogÉnicas y de generar vacunas combinadas contra entidades patogenas. Estas formulaciones pueden ser aplicadas en la industria farmacÉutica para uso profilActico y/o terapÉutico en humanos.
Priority Applications (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU20010171A CU23244A1 (es) | 2001-07-16 | 2001-07-16 | Formulacion vacunal potenciada por la combinacion de un adn con un antigeno |
MYPI20022620A MY134885A (en) | 2001-07-16 | 2002-07-10 | Vaccine formulation potentiated by the combination of dna and an antigen |
CA 2453260 CA2453260C (en) | 2001-07-16 | 2002-07-12 | Vaccine formulation potentiated by the combination of a dna and an antigen |
MXPA04000431A MXPA04000431A (es) | 2001-07-16 | 2002-07-12 | Formulacion vacunal potenciada por la combinacion de un adn con un antigeno. |
RU2004104357A RU2294212C2 (ru) | 2001-07-16 | 2002-07-12 | Вакцинный состав, потенцированный комбинацией днк и антигена |
BR0211181-0A BR0211181A (pt) | 2001-07-16 | 2002-07-12 | Formulação vacinal |
KR1020047000574A KR100905249B1 (ko) | 2001-07-16 | 2002-07-12 | Dna와 항원의 조합에 의해 효능이 증강된 백신포뮬레이션 |
CNB028142829A CN1241644C (zh) | 2001-07-16 | 2002-07-12 | 被dna和抗原组合增效的疫苗制剂 |
EP20020760072 EP1417973B1 (en) | 2001-07-16 | 2002-07-12 | Vaccine formulation potentiated by the combination of a dna and an antigen |
ES02760072T ES2393546T3 (es) | 2001-07-16 | 2002-07-12 | Formulación de vacuna potenciada mediante la combinación de un ADN con un antígeno |
PCT/CU2002/000005 WO2003007986A2 (es) | 2001-07-16 | 2002-07-12 | Formulacion vacunal potenciada por la combinacion de un adn con un antigeno |
ARP020102614 AR034771A1 (es) | 2001-07-16 | 2002-07-12 | Formulacion vacunal potenciada por la combinacion de un adn con un antigeno |
US10/484,112 US20040234543A1 (en) | 2001-07-16 | 2002-07-12 | Vaccine formulation potentiated by the combination of a dna and an antigen |
AU2002325783A AU2002325783B2 (en) | 2001-07-16 | 2002-07-12 | Vaccine formulation potentiated by the combination of a DNA and an antigen |
JP2003513591A JP4217611B2 (ja) | 2001-07-16 | 2002-07-12 | Dnaおよび抗原の併用により作用増強したワクチン製剤 |
ZA200400286A ZA200400286B (en) | 2001-07-16 | 2004-01-14 | Vaccine formulation potentiated by the combination of a DNA and an antigen. |
US12/430,534 US8691234B2 (en) | 2001-07-16 | 2009-04-27 | Vaccine formulation potentiated by the combination of DNA and an antigen |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU20010171A CU23244A1 (es) | 2001-07-16 | 2001-07-16 | Formulacion vacunal potenciada por la combinacion de un adn con un antigeno |
Publications (1)
Publication Number | Publication Date |
---|---|
CU23244A1 true CU23244A1 (es) | 2007-10-17 |
Family
ID=40091632
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU20010171A CU23244A1 (es) | 2001-07-16 | 2001-07-16 | Formulacion vacunal potenciada por la combinacion de un adn con un antigeno |
Country Status (16)
Country | Link |
---|---|
US (2) | US20040234543A1 (es) |
EP (1) | EP1417973B1 (es) |
JP (1) | JP4217611B2 (es) |
KR (1) | KR100905249B1 (es) |
CN (1) | CN1241644C (es) |
AR (1) | AR034771A1 (es) |
AU (1) | AU2002325783B2 (es) |
BR (1) | BR0211181A (es) |
CA (1) | CA2453260C (es) |
CU (1) | CU23244A1 (es) |
ES (1) | ES2393546T3 (es) |
MX (1) | MXPA04000431A (es) |
MY (1) | MY134885A (es) |
RU (1) | RU2294212C2 (es) |
WO (1) | WO2003007986A2 (es) |
ZA (1) | ZA200400286B (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU23496A1 (es) * | 2004-09-03 | 2010-02-23 | Ct Ingenieria Genetica Biotech | Composición vacunal contra el virus de la hepatitis c |
CN101437547A (zh) | 2005-01-20 | 2009-05-20 | 自然科技公司 | 用于遗传免疫的载体和方法 |
AU2008262478C1 (en) | 2007-05-29 | 2014-06-19 | Aldevron, L.L.C. | Vectors and methods for genetic immunization |
CN104830789A (zh) * | 2015-05-05 | 2015-08-12 | 杨光华 | 基于hcv1抗原的dc细胞、靶向性免疫细胞群及其制备方法和用途 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT400724B (de) * | 1989-12-18 | 1996-03-25 | Wellcome Found | Virales polypeptid |
CA2044296A1 (en) * | 1990-06-12 | 1991-12-13 | Hiroaki Okamoto | Oligonucleotide primers, and their application for high-fidelity detection of non-a, non-b hepatitis virus |
US7070790B1 (en) * | 1993-06-29 | 2006-07-04 | The United States Of America As Represented By The Department Of Health And Human Services | Nucleotide and deduced amino acid sequences of the envelope 1 and core genes of isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines |
US6689757B1 (en) * | 1996-02-12 | 2004-02-10 | M.L. Laboratories Plc | Methods for vaccination and vaccines therefor |
CU22642A1 (es) * | 1996-12-12 | 2000-12-22 | Ct Ingenieria Genetica Biotech | Secuencia de adnc derivadas del genoma del virus de la hepatitis c y su uso |
CN1044092C (zh) * | 1997-02-26 | 1999-07-14 | 上海医科大学 | 抗原-抗体-重组dna复合型疫苗 |
FR2760367B1 (fr) * | 1997-03-06 | 1999-04-30 | Pasteur Merieux Serums Vacc | Composition vaccinale destinee a la prevention ou au traitement des hepatites c |
EP0980434B1 (en) * | 1997-05-06 | 2009-07-29 | Novartis Vaccines and Diagnostics, Inc. | Intracellular production of hepatitis c e2 truncated polypeptid |
US6153421A (en) * | 1997-07-18 | 2000-11-28 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Cloned genomes of infectious hepatitis C viruses and uses thereof |
GB9726555D0 (en) * | 1997-12-16 | 1998-02-11 | Smithkline Beecham Plc | Vaccine |
DE19915178A1 (de) * | 1999-04-03 | 2000-10-05 | Univ Mainz Johannes Gutenberg | Hepatitis C Virus Zellkultursystem |
DE60040755D1 (de) * | 1999-12-01 | 2008-12-18 | Novartis Vaccines & Diagnostic | Hervorrufen von antikörpern spezifisch für hepatitis c virus (hcv) |
-
2001
- 2001-07-16 CU CU20010171A patent/CU23244A1/es unknown
-
2002
- 2002-07-10 MY MYPI20022620A patent/MY134885A/en unknown
- 2002-07-12 JP JP2003513591A patent/JP4217611B2/ja not_active Expired - Fee Related
- 2002-07-12 ES ES02760072T patent/ES2393546T3/es not_active Expired - Lifetime
- 2002-07-12 CN CNB028142829A patent/CN1241644C/zh not_active Expired - Fee Related
- 2002-07-12 RU RU2004104357A patent/RU2294212C2/ru not_active IP Right Cessation
- 2002-07-12 KR KR1020047000574A patent/KR100905249B1/ko not_active IP Right Cessation
- 2002-07-12 EP EP20020760072 patent/EP1417973B1/en not_active Expired - Lifetime
- 2002-07-12 AU AU2002325783A patent/AU2002325783B2/en not_active Ceased
- 2002-07-12 BR BR0211181-0A patent/BR0211181A/pt not_active IP Right Cessation
- 2002-07-12 AR ARP020102614 patent/AR034771A1/es not_active Application Discontinuation
- 2002-07-12 CA CA 2453260 patent/CA2453260C/en not_active Expired - Fee Related
- 2002-07-12 US US10/484,112 patent/US20040234543A1/en not_active Abandoned
- 2002-07-12 WO PCT/CU2002/000005 patent/WO2003007986A2/es active Application Filing
- 2002-07-12 MX MXPA04000431A patent/MXPA04000431A/es active IP Right Grant
-
2004
- 2004-01-14 ZA ZA200400286A patent/ZA200400286B/en unknown
-
2009
- 2009-04-27 US US12/430,534 patent/US8691234B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US8691234B2 (en) | 2014-04-08 |
WO2003007986A2 (es) | 2003-01-30 |
US20040234543A1 (en) | 2004-11-25 |
AR034771A1 (es) | 2004-03-17 |
CN1241644C (zh) | 2006-02-15 |
MXPA04000431A (es) | 2004-03-18 |
CA2453260A1 (en) | 2003-01-30 |
BR0211181A (pt) | 2004-08-10 |
EP1417973A2 (en) | 2004-05-12 |
JP2004537552A (ja) | 2004-12-16 |
WO2003007986A3 (es) | 2004-03-04 |
RU2294212C2 (ru) | 2007-02-27 |
MY134885A (en) | 2007-12-31 |
CA2453260C (en) | 2013-03-19 |
EP1417973B1 (en) | 2012-08-29 |
ES2393546T3 (es) | 2012-12-26 |
KR20040028924A (ko) | 2004-04-03 |
ZA200400286B (en) | 2004-10-04 |
WO2003007986A8 (es) | 2004-04-29 |
KR100905249B1 (ko) | 2009-06-29 |
JP4217611B2 (ja) | 2009-02-04 |
AU2002325783B2 (en) | 2006-08-17 |
RU2004104357A (ru) | 2005-07-10 |
CN1529616A (zh) | 2004-09-15 |
US20100316669A1 (en) | 2010-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2157447T3 (es) | Composicion de vacuna que comprende un antigeno de polisacarido conjugado adsorbido en fosfato de aluminio. | |
CR11122A (es) | Vacuna de influenza de emulsion de aceite en agua | |
NO20023829D0 (no) | Proteosom influensavaksine | |
BR0014281A (pt) | Vacina contra vìrus de gripe intranasal | |
EP1594536A4 (en) | ADJUVANT INFLUENZA VACCINE | |
IS4518A (is) | Nýtt lyfjaform fyrir bóluefni | |
TW200722101A (en) | Novel composition | |
DK1361890T3 (da) | Influenzavaccineformuleringer til intradermal indgift | |
CY1118521T1 (el) | Συνθεση εμβολιου και μεθοδος χρησης αυτου | |
PT1187629E (pt) | Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador | |
CY1113078T1 (el) | Συνθεση πολυσθενους εμβολιου | |
AR014182A1 (es) | Composiciones de vacunas utiles para el tratamiento o profilaxis de tumores o lesiones inducidas por hpv; procedimiento para prevenir o tratar tumoresinducidos por hpv y procedimiento para preparar dichas composiciones | |
ES2192582T3 (es) | Composicion de vaccineo, conteniendo quitina, parcialmente deacetilado. | |
NO20065480L (no) | Vaksiner. | |
BR112022014830A2 (pt) | Formulações de vacina para coronavírus | |
GB2386072A (en) | Novel vaccine | |
AR023535A1 (es) | Nuevas composiciones. | |
DK1259259T3 (da) | Mucosal adjuvansformulering | |
UY26882A1 (es) | Nuevo tratamiento | |
ATE458496T1 (de) | Hiv-vakzine und anwendungsverfahren | |
BR112023019301A2 (pt) | Formulações de vacina de coronavírus | |
CU23244A1 (es) | Formulacion vacunal potenciada por la combinacion de un adn con un antigeno | |
BR112023021812A2 (pt) | Composição vacinal adjuvantada e métodos | |
CU23496A1 (es) | Composición vacunal contra el virus de la hepatitis c | |
AR023536A1 (es) | Vacunas |